articleTop 1% cited

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

The Lancet Oncology · 2017 · Vol. 18(3) · pp. 312–322

Padmanee Sharma✉(The University of Texas MD Anderson Cancer Center)Margitta Retz(Klinikum rechts der Isar)Arlene O. Siefker‐Radtke(The University of Texas MD Anderson Cancer Center)Ari David Baron(California Pacific Medical Center)Andrea Necchi(Fondazione IRCCS Istituto Nazionale dei Tumori)Jens Bedke(University of Tübingen)Elizabeth R. Plimack(Fox Chase Cancer Center)Daniel A. Vaena(University of Iowa)Marc‐Oliver Grimm(Jena University Hospital)Sergio Bracarda(Ospedale San Donato)José Ángel Arranz(Hospital General Universitario Gregorio Marañón)Sumanta K. Pal(City of Hope)Chikara Οhyama(Hirosaki University)Abdel Saci(Bristol-Myers Squibb (United States))Xiaotao Qu(Bristol-Myers Squibb (United States))Alexandre Lambert(Bristol-Myers Squibb (Belgium))Suba Krishnan(Bristol-Myers Squibb (United States))Alex Azrilevich(Bristol-Myers Squibb (United States))Matthew D. Galsky(Tisch Cancer Institute)

View via DOI Publisher page

Bladder and Urothelial Cancer Treatments Cancer Immunotherapy and Biomarkers Urinary and Genital Oncology StudiesMedicineMetastatic Urothelial CarcinomaNivolumabRegimenInternal medicineClinical endpointOncologyChemotherapyResponse Evaluation Criteria in Solid TumorsPhases of clinical research

MeSH terms

NivolumabAdultAgedAged, 80 and overAntibodies, MonoclonalAntineoplastic AgentsCarcinoma, Transitional CellFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm Recurrence, LocalNeoplasm Staging

Citations

1,734

FWCI

201.15

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Phytochemical analysis, analgesic, anti-inflammatory, antispasmodics and antioxidants activities of Chenopodium album